Developing new antifungal peptides to fight resistant infections
Official title: Optimization and Characterization of Novel Antifungal Peptides
Funded at Aimmax Therapeutics, INC. · NIH-10620239 · Data updated 2026-11-12
This study is working on developing new treatments to help fight tough fungal infections, like invasive candidiasis, especially for patients who have infections that don't respond to current medicines.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aimmax Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | May 10, 2022 |
| Project end | April 30, 2026 |
| Funding year | 2023 |
| Award (this year) | $306,408 |
| NIH project number | 5R43AI164986-02 |
| Project ID | NIH-10620239 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from invasive candidiasis or those at high risk for fungal infections, particularly those with resistant strains.
✕Less likely to help
Patients with fungal infections that are not caused by Candida species may not benefit from this research.
What this research studies
This research focuses on creating and optimizing a new class of antifungal peptides to combat invasive candidiasis, a serious infection caused by fungi. The approach involves designing peptides that can effectively target and kill various Candida species, including those resistant to existing treatments. The research utilizes both in vitro and in vivo testing to evaluate the effectiveness and safety of these peptides, aiming to provide a novel therapeutic option for patients suffering from resistant fungal infections.
Why it matters
Potential benefit: If successful, this research could lead to new antifungal treatments that are effective against drug-resistant fungal infections, improving patient outcomes.
How similar studies have gone: Previous research has shown promise in developing antimicrobial peptides, indicating potential for success in this novel approach.
Where this research is happening
-
Aimmax Therapeutics, INC.
Durham, United States Active
Researchers
- Principal investigator: Keedy, Kara S — Aimmax Therapeutics, INC.
- Study coordinator: Keedy, Kara S
Related research
Other NIH-funded projects on the same topics.
-
A new oral pill to treat drug-resistant gonorrhea
This project aims to create an oral antibiotic that can treat gonorrhea that no longer responds to current drugs and might also cover common chlamydia co-infections.
-
Creating a new oral antibiotic to treat drug-resistant gonorrhea
This study is testing a new oral antibiotic that aims to effectively treat drug-resistant gonorrhea and chlamydia in one easy-to-take pill, making it simpler for people to stick to their treatment and helping tackle the rising issue of antibiotic resistance.
-
Creating a new injectable antibiotic for serious drug-resistant infections
This study is testing a new antibiotic called AMX-2005 to see if it can help treat serious infections caused by tough bacteria like MRSA and VRE, giving hope to patients who need better options when current treatments don’t work.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.